How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...
The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...
Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...
RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...
Vision Marine Technologies Announces Pricing of Public Offering of 32M Units; Expects Gross Proceeds of $9.6M; Offering Expected to Close Dec. 19; Plans to Use Proceeds for General Corporate Purposes, ...
Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback